Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
27
Recruiting, any sponsor type, condition "irritable bowel syndrome"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed234
27 trials
Showing 1 to 25, recently updated first.
Stanford UniversityAcademic, hospital or other
NCT07238790 · 13 participants (planned) · Start Mar 10, 2026 · Primary completion Dec 2028
Drug: MITI-001 administration · For: IBS (Irritable Bowel Syndrome); Diarrhea
Sites: Redwood City, California; Stanford, California
Johns Hopkins UniversityAcademic, hospital or other
NCT07768267 · 40 participants (planned) · Start Oct 26, 2026 · Primary completion Dec 31, 2027
Drug: Biocidin REMOVE; Placebo · For: Irritable Bowel Syndrome (IBS); Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Sites: Baltimore, Maryland
- A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Constipation (IBS-C)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07545772 · 342 participants (planned) · Start Apr 29, 2026 · Primary completion Jul 2027
Drug: LY3537031; Placebo · For: Irritable Bowel Syndrome; Constipation
Sites: Mesa, Arizona; Anaheim, California; Lancaster, California · 70 sites in all
- A Study of Brenipatide (LY3537031) in Participants With Irritable Bowel Syndrome-Diarrhea (IBS-D)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07545759 · 531 participants (planned) · Start May 6, 2026 · Primary completion Sep 2027
Drug: LY3537031; Placebo · For: Irritable Bowel Syndrome; Diarrhea
Sites: Mesa, Arizona; Anaheim, California; Lancaster, California · 89 sites in all
Aziz Bhatti Shaheed Teaching HospitalAcademic, hospital or other
NCT07914478 · 48 participants (planned) · Start Sep 1, 2026 · Primary completion Mar 30, 2027
Drug: Vitamin D3; Placebo · For: Irritable Bowel Syndrome (IBS); Vitamin D Deficiency
Sites: Gujrat, Pakistan
- A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)Pivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07519395 · 420 participants (planned) · Start Apr 8, 2026 · Primary completion Mar 9, 2027
Drug: Placebo; Camlipixant · For: Irritable Bowel Syndrome
Sites: Anniston, Alabama; Guntersville, Alabama; Mobile, Alabama · 114 sites in all
- Home Transcutaneous Electrical Acustimulation (TEA)Pivotal-lookingRecruiting
University of MichiganAcademic, hospital or other
NCT05519683 · 160 participants (planned) · Start Nov 2, 2022 · Primary completion Mar 2027
Drug: Lexapro · For: Irritable Bowel Syndrome With Constipation
Sites: Ann Arbor, Michigan
- Efficacy of Esketamine for Patients With Irritable Bowel SyndromePivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT06788444 · 552 participants (planned) · Start Feb 8, 2025 · Primary completion Dec 31, 2026
Drug: Esketamine · For: Irritable Bowel Syndrome
Sites: Beijing, China
Hospices Civils de LyonAcademic, hospital or other
NCT06801184 · 40 participants (planned) · Start Feb 10, 2025 · Primary completion Oct 10, 2028
Drug: Plasma Sample; Stool Sample · For: Irritable Bowel Syndrome
Sites: Lyon, France
- Efficacy of Pregabalin for Patients With Irritable Bowel SyndromePivotal-lookingRecruiting
Beijing Tiantan HospitalAcademic, hospital or other
NCT07635394 · 258 participants (planned) · Start Apr 7, 2026 · Primary completion Apr 8, 2026
Drug: The pregabalin group; Routine Treatment · For: Irritable Bowel Syndrome (IBS)
Sites: Beijing, China
University Medical Center Ho Chi Minh City (UMC)Academic, hospital or other
NCT07000383 · 90 participants (planned) · Start Jun 15, 2025 · Primary completion Jul 30, 2026
Drug: Antispasmodic Agent · For: Diarrhea-predominant Irritable Bowel Syndrome; Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Sites: Ho Chi Minh City, Vietnam
- Psyllium in Pediatric IBSPivotal-lookingRecruiting
Dr Bruno Chumpitazi, M.D.Academic, hospital or other
NCT06639984 · 110 participants (planned) · Start Feb 20, 2025 · Primary completion Sep 30, 2027
Drug: Psyllium (0.7 g/year of age per day); Psyllium (0.5 g/year of age per day) and 1 more · For: Irritable Bowel Syndrome
Sites: Durham, North Carolina
- Fecal Microbiota Transplantation for IBSRecruiting
Madhusudan (Madhu) Grover, MBBSAcademic, hospital or other
NCT05776914 · 43 participants (planned) · Start Apr 15, 2024 · Primary completion Jun 26, 2027
Drug: Donor Fecal Microbiota Transplantation; Autologous Fecal Microbiota Transplantation · For: Irritable Bowel Syndrome; Diarrhea
Sites: Rochester, Minnesota
- Efficacy of Rifaximin With NAC in IBS-DPivotal-lookingRecruiting
Mark Pimentel, MDAcademic, hospital or other
NCT06727422 · 225 participants (planned) · Start Feb 4, 2026 · Primary completion Aug 1, 2026
Drug: rifaximin 66mg + N-acetylcysteine 560mg three times daily; RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily and 1 more · For: IBS (Irritable Bowel Syndrome); IBS-D (Diarrhea-predominant)
Sites: Los Angeles, California
- Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel SyndromePivotal-lookingRecruiting
Devintec SaglIndustry
NCT06681012 · 330 participants (planned) · Start Oct 22, 2024 · Primary completion Jul 2027
Drug: Placebo · For: Irritable Bowel Syndrome (IBS); Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Sites: Leuven, Belgium; Bobigny, France; Rouen, France · 12 sites in all
- Effectiveness of a Dietary Supplement in Irritable Bowel SyndromePivotal-lookingRecruiting
University Hospital, RouenAcademic, hospital or other
NCT07039747 · 100 participants (planned) · Start Apr 22, 2025 · Primary completion Feb 2027
Drug: treatment with DIELEN® Protect; treatment with placebo of DIELEN® Protect · For: Irritable Bowel Syndrome
Sites: Rouen, France
Valenta Pharm JSCIndustry
NCT07421011 · 36 participants (planned) · Start Nov 6, 2025 · Primary completion Dec 31, 2026
Drug: Trimedat® · For: Irritable Bowel Syndrome; Gallstone Disease; GERD and 2 more
Sites: Saint Petersburg, Russia
Mayo ClinicAcademic, hospital or other
NCT06684470 · 20 participants (planned) · Start Dec 19, 2024 · Primary completion Dec 19, 2026
Drug: Mirtazapine · For: IBS - Irritable Bowel Syndrome; Diarrhea
Sites: Jacksonville, Florida
- Saccharomyces Boulardii CNCM I-745 in Irritable Bowel SyndromePivotal-lookingRecruiting
BiocodexIndustry
NCT07168434 · 406 participants (planned) · Start Oct 22, 2025 · Primary completion Oct 11, 2026
Drug: Saccharomyces Boulardii 250 MG; Placebo 250 mg · For: IBS (Irritable Bowel Syndrome); IBS-D (Diarrhea-predominant); IBS, Mixed Symptoms
Sites: Braga, Portugal; Lisbon, Portugal; Barcelona, Spain · 10 sites in all
- Effect of Ebastine in Patients With Diarrhea Predominant Irritable Bowel SyndromePivotal-lookingRecruiting
Md. Hazrat AliAcademic, hospital or other
NCT07114055 · 60 participants (planned) · Start Aug 15, 2025 · Primary completion Jul 2026
Drug: ebastine; Placebo · For: Irritable Bowel Syndrome - Diarrhoea
Sites: Dhaka, Bangladesh
Medical University of GdanskAcademic, hospital or other
NCT06917963 · 80 participants (planned) · Start Apr 10, 2025 · Primary completion Jun 2027
Drug: Intensified intravenous omeprazole therapy (loading dose 80 mg IV, then 40 mg IV twice daily at 6:00 AM and 6:00 PM); Standard intravenous omeprazole therapy (40 mg IV once daily at 6:00 AM). · For: Stoma - Ileostomy; High Output Stoma; Colon Cancer and 3 more
Sites: Gdansk, Poland; Gdynia, Poland
The First Affiliated Hospital of Soochow UniversityAcademic, hospital or other
NCT06960369 · 400 participants (planned) · Start Dec 1, 2024 · Primary completion Jun 1, 2026
Drug: shamrTMS combined with Live Probiotic tablet · For: Irritable Bowel Syndrome; Irritable Bowel Syndrome With Diarrhea (IBS-D); Repetitive Transcranial Magnetic Stimulation (rTMS) and 3 more
Sites: Suzhou, China
- A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-DPivotal-lookingRecruiting
Guangzhou Zhiyi Biotechnology Co., Ltd.Academic, hospital or other
NCT06247046 · 1,298 participants (planned) · Start Mar 16, 2024 · Primary completion Apr 2026
Drug: Live SK08 powder; Placebo · For: Irritable Bowel Syndrome With Diarrhea
Sites: Wuxi, China; Binzhou, China
- The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue SyndromePivotal-lookingRecruiting
Nova Southeastern UniversityAcademic, hospital or other
NCT06211062 · 100 participants (planned) · Start Dec 20, 2022 · Primary completion Feb 24, 2026
Drug: Floradapt Intensive GI · For: ME/CFS; IBS - Irritable Bowel Syndrome
Sites: Fort Lauderdale, Florida
Xiyuan Hospital of China Academy of Chinese Medical SciencesAcademic, hospital or other
NCT06737666 · 60 participants (planned) · Start May 29, 2023 · Primary completion Oct 8, 2025
Drug: Tong-Xie-Yao-Fang · For: Diarrhea-predominant Irritable Bowel Syndrome
Sites: Beijing, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.